Having demonstrated a molecular antagonism between PRL/PRLR pathway and YAP-CCN2 pathway in mammary and breast cancer cells, we next sought to determine the clinical impact of this antagonism regarding breast cancer prognosis and potential therapeutic value. The gene discussed is CCN2; the disease is breast carcinoma.